



17W

Attorney Docket No. UNI.26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	JIA	}	EXAMINER:	WINSTON, R.O.
SERIAL NO.:	10/817,330		ART UNIT:	1654
FILED:	April 02, 2004		CONFIRMATION NO.:	1136
TITLE:	FORMULATION OF DUAL CYCLOXYGENASE (COX) AND LIPOXYGENASE (LOX) INHIBITORS FOR MAMMAL SKIN CARE			

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

37 CFR 1.8


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 8/23/04.

Signature: Denise S. Magee
Name: Denise S. Magee


Respectfully submitted,

Date: August 23, 2004


Rosemary P. Kellogg, #39,266
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
303-268-0066 Telephone
303-268-0065 Facsimile

cc: Qi Jia

S:\CLIENT FOLDERS\UNIGEN PHARMACEUTICALS\UNI26\UTILITY\IDS WITHOUT OPTIONS.DOC



U.S. DEPARTMENT OF
COMMERCE PATENT
AND TRADEMARK
OFFICE

List of Information Cited by Applicant

Page 1 of 3

ATTY. DOCKET NO.

UNI.26

SERIAL NO.

10/817,330

APPLICANT

JIA

FILING DATE

04-02-2004

GROUP

U.S. PATENT DOCUMENTS

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	4,946,684	08-07-1990	BLANK <i>et al.</i>			
	AB	5,443,983	08-22-1995	OCHOA <i>et al.</i>			
	AC	5,470,589	11-28-1995	SHI			
	AD	5,545,411	08-13-1996	CHANCELLOR			
	AE	5,605,929	02-25-1997	LIAO <i>et al.</i>			
	AF	5,643,598	07-01-1997	MAYBECK			
	AG	5,651,987	07-29-1997	FUISZ			
	AH	5,756,538	05-26-1998	CASSELS <i>et al.</i>			
	AI	5,795,911	08-18-1998	CHENG <i>et al.</i>			
	AJ	5,858,371	01-12-1999	SINGH <i>et al.</i>			
	AK	5,886,029	03-23-1999	DHALIWAL			
	AL	5,922,756	07-13-1999	CHAN			
	AM	5,962,517	10-05-1999	MURAD			
	AN	5,968,973	10-19-1999	CHENG <i>et al.</i>			
	AO	6,083,921	07-04-2000	XU			
	AP	6,093,403	07-25-2000	HUO <i>et al.</i>			
	AQ	6,126,940	10-03-2000	TAKAHASHI <i>et al.</i>			
	AR	6,126,950	10-03-2000	BINDRA <i>et al.</i>			
	AS	6,197,808	06-03-2001	CHENG <i>et al.</i>			
	AT	6,217,875	04-17-2001	MURAI <i>et al.</i>			
	AU	6,235,294	05-22-2001	PERRIER <i>et al.</i>			
	AV	6,248,341	06-19-2001	ANDERSON <i>et al.</i>			
	AW	6,264,995	07-24-2001	NEWMARK <i>et al.</i>			
	AX	6,290,995	09-18-2001	XINXIAN			
	AY	6,387,416	05-14-2002	NEWMARK <i>et al.</i>			
	AZ	6,391,346	05-21-2002	NEWMARK <i>et al.</i>			
	AAA	6,475,530	11-05-2002	KUHRTS			
	ABB	US 2002/0086070	07/04/2002	KUHRTS			
	ACC	US 2002/0122836	09/05/2002	OBUKOWICZ <i>et al.</i>			
	ADD	US 2002/0136784	09/26/2002	OBUKOWICZ <i>et al.</i>			
	AEE						
	AFF						

S:\Client Folders\UniGen Pharmaceuticals\UNI26\UTILITY\IDS without options.doc

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 3	ATTY. DOCKET NO. UNI.26	SERIAL NO. 10/817,330
	APPLICANT JIA	
	FILING DATE 04-02-2004	GROUP

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	BA	EP 0956867A1	11-17-1999	EUROPE (Including English Translation of Abstract)			
	BB	JP 403240725	10-28-1991	JAPAN			
	BC	JP 2002053484	02-19-2002	JAPAN			
	BD						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
BE	Afolayan and Meyer (1997) Journal of Ethnopharmacol. 57(3):177-181
BF	Agarwal <i>et al.</i> (1993) Photochem. Photobiol. 58:695-700
BG	Amos <i>et al.</i> (1999) Phytotherapy Research 13:683-685 (Abstract only)
BH	Ardlie <i>et al.</i> (1985) Thromb. Res. 38(6):695-706
BI	Bastianetto <i>et al.</i> (2000) Br. J. Pharmacol. 131:711-720
BJ	Bosset (2003) Br. J. Dermatol. 149(4):826-835
BK	Boumendjel <i>et al.</i> (2001) Bioorg. Med. Chem. Lett. 11(1):75-77
BL	Brideau <i>et al.</i> (1996) Inflamm. Res. 45:68-74
BM	Chen <i>et al.</i> (2001) Biochem. Pharmacol. 61(11):1417-1427
BN	Chi <i>et al.</i> (2001) Biochem. Pharmacol. 61:1195-1203
BO	Commenges <i>et al.</i> (April 2000) Eur. J. Epidemiol 16:357-363 (Abstract)
BP	Dafallah and Al-Mustafa (1996) American Journal of Chinese Medicine. 24:263-269 (Abstract only)
BQ	Friedman (Sept. 2002) J. Cutan Med. Surg. 6(5):449-459.
BR	Gilani <i>et al.</i> (December 1999) Phytotherapy Research. 13:665-669 (Abstract only)
BS	Hagos <i>et al.</i> (February 1987) Planta Medica. 53:27-31
BT	Hanausek-Walaszek <i>et al.</i> (March 2000) Proceedings American Association for Cancer Research Annual Meeting 41:663 (abstract #4216)
BU	Haridas <i>et al.</i> (March 2000) Proceedings American Association for Cancer Research Annual Meeting. 41:600 (abstract #3820)
BV	Hase (2000) Br. J. Dermatol. 142(2):267
BW	Heo <i>et al.</i> (2001) Mutat. Res. 488(2):135-150
BX	Hong <i>et al.</i> (2001) Biochem. Pharmacol. 62:1175-1183
BY	Imamura <i>et al.</i> (2000) J. Biochem. 127(4):653-658
BZ	Itoigawa <i>et al.</i> (1999) J. Ethnopharmacol. 65(3): 267-272
BAA	Kalkbrenner <i>et al.</i> (1992) Pharmacology 44(1):1-12
BBB	Kaneko and Baba (1999) Biosci Biotechnol. Biochem 63(2):323-328
BCC	Kimura <i>et al.</i> (2001) Planta Med. 67:331-334
BBC	Kuhn (1988) Biomed. Biochim. Acta. 47:S320

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 3 of 3		ATTY. DOCKET NO. UNI.26	SERIAL NO. 10/817,330
		APPLICANT JIA	
		FILING DATE 04-02-2004	GROUP
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	CA	Krakauer et al. (2001) FEBS Lett. 500:52-55	
	CB	Kubo et al. (2000) Bioorg. Med. Chem. 8(7):1749-1755	
	CC	Lee (2003) Dermatol Surg 29(12):1196-1199	
	CD	Leyden (2003) J. Am. Acad. Dermatol. 49(3 Suppl):S200	
	CE	Li et al. (2000) Immunopharmacology 49:295-306	
	CF	Liang et al. (2001) FEBS Lett. 496(1):12-18	
	CG	Meyer et al. (1997) J. Ethnopharmacol. 56(2):165-169	
	CH	Millikan (2003) Am. J. Clin. Dermatol. 4(2):75-80	
	CI	Min et al. (1999) Planta Med. 65:460-462	
	CJ	Moroney et al. (1988) J. Pharm. Pharmacol. 40:787-792	
	CK	Mutoh et al. (July 2000) Jnp. J. Cancer Res. 91:686-691 (Abstract Only)	
	CL	Nadkarni (1996) India Materia Medica, Bombay Popular Prakashan, pp. 9-17	
	CM	Nakahata et al. (1998) Am. J. Chin Med. 26:311-323 (English Abstract)	
	CN	Nakahata et al. (1999) Nippon Yakurigaku Zasshi, 114, Supp. 11:215P-219P (English Abstract)	
	CO	Nakajima et al. (2001) Planta Med. 67(2):132-135	
	CP	Nakamura (2003) Free Radical Biol. Med. 35(9):997-1007	
	CQ	Noreen et al. (1998) Planta Med. 64:520-524	
	CR	Noreen et al. (Jan. 1998) J. Nat. Prod. 61:2-7	
	CS	Noreen et al. (Jan. 1998) J. Nat. Prod. 61:8-12	
	CT	Park et al. (2001) Biochem. Biophys. Res. Commun. 286:721-725	
	CU	Phillips et al. (1997) J. Am. Acad. Dermatol. 37(6):948-952	
	CV	de la Puerta et al. (1999) Planta Medica 65:507-511	
	CW	Raso et al. (2001) Life Sci. 68(8):921-931	
	CX	Salmon et al. (1985) Prostaglandins 29(3):377-385	
	CY	Sekine et al. (1997) Chemical and Pharmaceutical Bulletin. 45:148-11	
	CZ	Shah et al. (1997) General Pharmacology. 29:251-255	
	CAA	So et al. (1997) Cancer Lett. 112(2):127-133	
	CBB	Sobottka et al. (2000) Arch. Pharm. Pharm. Med. Chem. 333:205-210	
	CCC	Tordera et al. (March-April 1994) Z. Naturforsch [C] 49:235-240 (abstract)	
	CDD	de Whalley et al. (1990) Biochemical Pharmacology 39:1743-1750	
	CEE	Wakabayashi and Yasui (2000) Eur. J. Pharmacol. 406(3):477-481	
	CFF	Wang (March 2000) Phytomedicine 7:15-19 (abstract)	
	CGG	Wenzel et al. (July 2000) Cancer Res. 60:3823-3831	
	CHH	Wilgus et al. (2000) Prostaglandins & other Lipid Mediators 62(4):367-384	
	CH	Wilgus et al. (2002) Adv. Exp. Med. Biol. 507:85-92	
	CKK	You et al. (1999) Arch. Pharm. Res. 22:18-24	
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			